Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 5mg | $49.00 | $9.80/mg | In stock | Jul 7 |
| vial | 10mg | $59.00 | $5.90/mg | In stock | Jul 7 |
| vial | 25mg | $89.00 | $3.56/mg | In stock | Jul 7 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| BPC25-10-001 | Sep 2025 | 99.9% | Janoshik Analytical | Endotoxin | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. BPC-157 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Skye Peptides sell BPC-157?
Yes — Skye Peptides currently lists BPC-157 in 3 variants starting at $89.00 ($3.56/mg).
Is Skye Peptides's BPC-157 third-party tested?
Yes — Disclosed Labs has indexed 4 Certificates of Analysis for Skye Peptides's BPC-157, with the most recent showing 99.9% purity. Skye Peptides holds an overall trust grade of B (85/100) across all 158 COAs on file.
What is Skye Peptides's trust grade for BPC-157?
Skye Peptides has an overall Disclosed Labs trust grade of B (85/100), computed from 158 COAs across all peptides. The most recent BPC-157 COA was issued by Janoshik Analytical.
Where is the cheapest BPC-157?
As of the latest data, Alpha Peptides offers BPC-157 at $1.82/mg — compare with Skye Peptides's listing at $3.56/mg. See the full BPC-157 price comparison.
Is BPC-157 legal to buy?
BPC-157 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| BPC25-20-003 | Aug 2025 | 100.0% | Janoshik Analytical | Endotoxin | Confirmed | View |
| BPC25-05-002 | Jul 2025 | 99.8% | Janoshik Analytical | Endotoxin | Confirmed | View |
| 01BPC157250 | Mar 2025 | — | Janoshik Analytical | — | Confirmed | View |
Disclosed Labs